308 related articles for article (PubMed ID: 35203589)
21. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
[TBL] [Abstract][Full Text] [Related]
22. Starring role of toll-like receptor-4 activation in the gut-liver axis.
Carotti S; Guarino MP; Vespasiani-Gentilucci U; Morini S
World J Gastrointest Pathophysiol; 2015 Nov; 6(4):99-109. PubMed ID: 26600967
[TBL] [Abstract][Full Text] [Related]
23. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.
Mima K; Ogino S; Nakagawa S; Sawayama H; Kinoshita K; Krashima R; Ishimoto T; Imai K; Iwatsuki M; Hashimoto D; Baba Y; Sakamoto Y; Yamashita YI; Yoshida N; Chikamoto A; Ishiko T; Baba H
Surg Oncol; 2017 Dec; 26(4):368-376. PubMed ID: 29113654
[TBL] [Abstract][Full Text] [Related]
24. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
25. Microbe-based management for colorectal cancer.
Gao ZY; Cui Z; Yan YQ; Ning LJ; Wang ZH; Hong J
Chin Med J (Engl); 2021 Dec; 134(24):2922-2930. PubMed ID: 34855639
[TBL] [Abstract][Full Text] [Related]
26. [Gut microbiota: What impact on colorectal carcinogenesis and treatment?].
Bruneau A; Baylatry MT; Joly AC; Sokol H
Bull Cancer; 2018 Jan; 105(1):70-80. PubMed ID: 29217301
[TBL] [Abstract][Full Text] [Related]
27. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
Brandl K; Schnabl B
Expert Rev Gastroenterol Hepatol; 2015; 9(8):1069-76. PubMed ID: 26088524
[TBL] [Abstract][Full Text] [Related]
28. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
[TBL] [Abstract][Full Text] [Related]
29. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
30. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
31. Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship.
Manilla V; Di Tommaso N; Santopaolo F; Gasbarrini A; Ponziani FR
Microorganisms; 2023 Jan; 11(2):. PubMed ID: 36838231
[TBL] [Abstract][Full Text] [Related]
32. The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease.
Chi M; Ma K; Wang J; Ding Z; Li Y; Zhu S; Liang X; Zhang Q; Song L; Liu C
J Immunol Res; 2021; 2021():5516035. PubMed ID: 34095319
[TBL] [Abstract][Full Text] [Related]
33. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
[TBL] [Abstract][Full Text] [Related]
34. Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic Inflammation.
Andersen K; Kesper MS; Marschner JA; Konrad L; Ryu M; Kumar Vr S; Kulkarni OP; Mulay SR; Romoli S; Demleitner J; Schiller P; Dietrich A; Müller S; Gross O; Ruscheweyh HJ; Huson DH; Stecher B; Anders HJ
J Am Soc Nephrol; 2017 Jan; 28(1):76-83. PubMed ID: 27151924
[TBL] [Abstract][Full Text] [Related]
35. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis.
Yu LC
J Biomed Sci; 2018 Nov; 25(1):79. PubMed ID: 30413188
[TBL] [Abstract][Full Text] [Related]
36. Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis.
Wang S; Dong W; Liu L; Xu M; Wang Y; Liu T; Zhang Y; Wang B; Cao H
Mol Carcinog; 2019 Jul; 58(7):1155-1167. PubMed ID: 30828892
[TBL] [Abstract][Full Text] [Related]
37. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis.
Gómez-Hurtado I; Santacruz A; Peiró G; Zapater P; Gutiérrez A; Pérez-Mateo M; Sanz Y; Francés R
PLoS One; 2011; 6(7):e23037. PubMed ID: 21829583
[TBL] [Abstract][Full Text] [Related]
38. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
39. Synbiotic VSL#3 and yacon-based product modulate the intestinal microbiota and prevent the development of pre-neoplastic lesions in a colorectal carcinogenesis model.
Dos Santos Cruz BC; da Silva Duarte V; Giacomini A; Corich V; de Paula SO; da Silva Fialho L; Guimarães VM; de Luces Fortes Ferreira CL; Gouveia Peluzio MDC
Appl Microbiol Biotechnol; 2020 Oct; 104(20):8837-8857. PubMed ID: 32902682
[TBL] [Abstract][Full Text] [Related]
40. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.
Seo YS; Shah VH
Clin Mol Hepatol; 2012 Dec; 18(4):337-46. PubMed ID: 23323248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
